United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Pharma Industry News Clearmind Medicine files U.S. patent for non-hallucinogenic MEAI therapy targeting cocaine addiction Find out how Clearmind Medicine’s new U.S. patent filing for its non-hallucinogenic MEAI therapy could transform cocaine addiction treatment and investor sentiment. bySoujanya RaviOctober 31, 2025